{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:03:31Z","timestamp":1764079411273,"version":"3.41.2"},"reference-count":116,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0041","PI17\/01518"],"award-info":[{"award-number":["RD16\/0025\/0041","PI17\/01518"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02429","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:48:01Z","timestamp":1540280881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies"],"prefix":"10.3389","volume":"9","author":[{"given":"Jorge","family":"Carrillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1056\/NEJM199905273402102","article-title":"Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy","volume":"340","author":"Furtado","year":"1999","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev.immunol.18.1.665","article-title":"Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy","volume":"18","author":"Pierson","year":"2000","journal-title":"Annu Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1182\/blood-2007-06-097907","article-title":"CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency","volume":"110","author":"Saleh","year":"2007","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrmicro1580","article-title":"Experimental approaches to the study of HIV-1 latency","volume":"5","author":"Han","year":"2007","journal-title":"Nat Rev Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11904-012-0150-8","article-title":"Attacking the HIV Reservoir from the Immune and Viral Perspective","volume":"10","author":"Massanella","year":"2013","journal-title":"Curr HIV\/AIDS Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1002417","DOI":"10.1371\/journal.pmed.1002417","article-title":"HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study","volume":"14","author":"Henrich","year":"2017","journal-title":"PLoS Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4049\/jimmunol.1600343","article-title":"The latent reservoir for HIV-1: how immunologic memory and clonal expansion contribute to HIV-1 persistence","volume":"197","author":"Murray","year":"2016","journal-title":"J Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.chom.2016.02.013","article-title":"Macrophages and HIV-1: an unhealthy constellation","volume":"19","author":"Sattentau","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/jac\/dky106","article-title":"Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs","volume":"73","author":"Puertas","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1093\/jac\/dkt183","article-title":"Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy","volume":"68","author":"Negredo","year":"2013","journal-title":"J Antimicrob Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/QAD.0b013e328359f20f","article-title":"Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV infected HAART-supressed individuals with poor CD4 T-cell recovery","volume":"26","author":"Massanella","year":"2012","journal-title":"AIDS"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3851\/IMP1917","article-title":"Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study","volume":"17","author":"Llibre","year":"2012","journal-title":"Antivir Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5897298","DOI":"10.1155\/2017\/5897298","article-title":"Aging in HIV-Infected Subjects: a new scenario and a new view","volume":"2017","author":"Negredo","year":"2017","journal-title":"Biomed Res Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.3390\/v10040157","article-title":"Tackling HIV persistence: pharmacological versus CRISPR-based shock strategies","volume":"10","author":"Darcis","year":"2018","journal-title":"Viruses"},{"key":"B16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/COH.0000000000000230","article-title":"Residual inflammation and viral reservoirs: alliance against an HIV cure","volume":"11","author":"Massanella","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"B17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1182\/blood-2008-10-186601","article-title":"IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection","volume":"113","author":"Sereti","year":"2009","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1128\/JVI.02638-15","article-title":"Replication of human herpesviruses is associated with higher HIV DNA levels during antiretroviral therapy started at early phases of HIV infection","volume":"90","author":"Gianella","year":"2016","journal-title":"J Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"99127","DOI":"10.1172\/jci.insight.99127","article-title":"HIV infection results in clonal expansions containing integrations within pathogenesis-related biological pathways","volume":"3","author":"Haworth","year":"2018","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev-med-092112-152941","article-title":"Understanding HIV latency: the road to an HIV cure","volume":"66","author":"Dahabieh","year":"2015","journal-title":"Annu Rev Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1172\/JCI97555","article-title":"Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells","volume":"128","author":"Huang","year":"2018","journal-title":"J Clin Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/QAD.0000000000001686","article-title":"Memory B cell dysregulation in HIV-1-infected individuals","volume":"32","author":"Carrillo","year":"2018","journal-title":"AIDS"},{"key":"B26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.micinf.2012.05.001","article-title":"Evasion from NK cell-mediated immune responses by HIV-1","volume":"14","author":"Jost","year":"2012","journal-title":"Microbes Infect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e00647","DOI":"10.1128\/JVI.00647-17","article-title":"Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46\/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells","volume":"91","author":"Marras","year":"2017","journal-title":"J Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e02233","DOI":"10.1128\/JVI.02233-16","article-title":"HIV-specific granzyme B-secreting but not gamma interferon-secreting T Cells are associated with reduced viral reservoirs in early HIV infection","volume":"91","author":"Yue","year":"2017","journal-title":"J Virol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1086\/340521","article-title":"Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4 + T cells and CD4 +:CD8 + T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy","volume":"185","author":"Chun","year":"2002","journal-title":"J Infect Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12879-017-2683-3","article-title":"Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing","volume":"17","author":"Thorlund","year":"2017","journal-title":"BMC Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.imlet.2018.02.004","article-title":"The role of latency reversal agents in the cure of HIV: a review of current data","volume":"196","author":"Bashiri","year":"2018","journal-title":"Immunol Lett."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Guti\u00e9rrez","year":"2016","journal-title":"AIDS"},{"key":"B35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","article-title":"Depletion of latent HIV-1 infection in vivo: a proof-of-concept study","volume":"366","author":"Lehrman","year":"2005","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1172\/JCI92684","article-title":"Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","volume":"127","author":"Archin","year":"2017","journal-title":"J Clin Inves.t"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-981-13-0484-2_2","article-title":"HIV T-cell vaccines","volume":"1075","author":"Mothe","year":"2018","journal-title":"Adv Exp Med Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2016.173","article-title":"Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection","volume":"15","author":"Ferrari","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1570162X15666171124122044","article-title":"The neutralizing antibody response to the HIV-1 env protein","volume":"16","author":"Moore","year":"2018","journal-title":"Curr HIV Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1517\/14728222.2015.1010513","article-title":"HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth","volume":"19","author":"Acharya","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"B44","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1126\/science.aae0474","article-title":"Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody","volume":"352","author":"Kong","year":"2016","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3389\/fimmu.2017.01154","article-title":"Immunologic Insights on the membrane proximal external region: a major human immunodeficiency virus type-1 vaccine target","volume":"8","author":"Molinos-Albert","year":"2017","journal-title":"Front Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.abb.2012.03.021","article-title":"Isotype and glycoform selection for antibody therapeutics","volume":"526","author":"Jefferis","year":"2012","journal-title":"Arch Biochem Biophys."},{"key":"B47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.1998.tb01188.x","article-title":"IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation","volume":"163","author":"Jefferis","year":"1998","journal-title":"Immunol Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tim.2015.07.005","article-title":"Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?","volume":"23","author":"Pelegrin","year":"2015","journal-title":"Trends Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection","volume":"66","author":"Kim","year":"2015","journal-title":"Annu Rev Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pharmthera.2016.03.007","article-title":"A comprehensive review of the neonatal Fc receptor and its application in drug delivery","volume":"161","author":"Martins","year":"2016","journal-title":"Pharmacol Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1084\/jem.20121827","article-title":"Neutralizing antibodies to HIV-1 induced by immunization","volume":"210","author":"McCoy","year":"2013","journal-title":"J Exp Med."},{"key":"B59","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J Virol."},{"key":"B60","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1128\/JVI.67.11.6642-6647.1993","article-title":"A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1","volume":"67","author":"Muster","year":"1993","journal-title":"J Virol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J Immunol Methods"},{"key":"B62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jim.2013.09.003","article-title":"Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160\u0394c(BaL","volume":"397","author":"Gaebler","year":"2013","journal-title":"J Immunol Methods"},{"key":"B63","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J Virol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11483","DOI":"10.1073\/pnas.1004600107","article-title":"Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1","volume":"107","author":"Pejchal","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B68","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B69","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.4161\/mabs.29883","article-title":"In vitro and in vivo modifications of recombinant and human IgG antibodies","volume":"6","author":"Liu","year":"2014","journal-title":"MAbs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","article-title":"Bispecific Anti-HIV-1 antibodies with enhanced breadth and potency","volume":"165","author":"Bournazos","year":"2016","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1006786","DOI":"10.1371\/journal.ppat.1006786","article-title":"eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients","volume":"13","author":"Davis-Gardner","year":"2017","journal-title":"PLoS Pathog."},{"key":"B78","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.4049\/jimmunol.1002600","article-title":"Fc-glycosylation influences Fc\u03b3 receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12","volume":"185","author":"Forthal","year":"2010","journal-title":"J Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"12675","DOI":"10.1073\/pnas.1509090112","article-title":"Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants","volume":"112","author":"Loos","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e00937-1","DOI":"10.1128\/JVI.00937-17","article-title":"Potent in vivo NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein","volume":"91","author":"Bardhi","year":"2017","journal-title":"J Virol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21037\/tcr.2017.01.08","article-title":"The role of novel immunotherapies in non-Hodgkin lymphoma","volume":"6","author":"Pishko","year":"2017","journal-title":"Transl Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1038\/ncomms9447","article-title":"Activation and lysis of human CD4 cells latently infected with HIV-1","volume":"6","author":"Pegu","year":"2015","journal-title":"Nat Commun."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1172\/JCI82314","article-title":"Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells","volume":"125","author":"Sung","year":"2015","journal-title":"J Clin Invest."},{"key":"B87","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/infdis\/168.2.298","article-title":"Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection","volume":"168","author":"Jacobson","year":"1993","journal-title":"J Infect Dis."},{"key":"B88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","article-title":"A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1","volume":"16","author":"Armbruster","year":"2002","journal-title":"AIDS"},{"key":"B89","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/jac\/dkh428","article-title":"Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12","volume":"54","author":"Armbruster","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12977-018-0434-1","article-title":"HIV-1 cell-to-cell transmission and broadly neutralizing antibodies","volume":"15","author":"Dufloo","year":"2018","journal-title":"Retrovirology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of broadly neutralizing antibodies for HIV-1 prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol Rev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e1002634","DOI":"10.1371\/journal.ppat.1002634","article-title":"Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies","volume":"8","author":"Abela","year":"2012","journal-title":"PLoS Pathog."},{"key":"B97","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/QAD.0b013e32831ef1a3","article-title":"Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells","volume":"23","author":"Massanella","year":"2009","journal-title":"AIDS"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1084\/jem.20131244","article-title":"Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission","volume":"210","author":"Malbec","year":"2013","journal-title":"J Exp Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1172\/JCI96764","article-title":"Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice","volume":"128","author":"Wu","year":"2018","journal-title":"J Clin Invest."},{"key":"B100","first-page":"26","article-title":"PGT121 combined with GS-9620 delays viral rebound in SHIV-infected rhesus monkeys","volume-title":"25th Conference on Retroviruses and Opportunistic Infections.","author":"Borducchi","year":"2018"},{"key":"B101","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"B103","first-page":"407","article-title":"A phase I dose-escalation study of monoclonal antibody VRC07-523LS in healthy adults","volume-title":"25th Conference on Retroviruses and Opportunistic Infections.","author":"Gaudinski","year":"2018"},{"key":"B104","first-page":"407","article-title":"A phase I trial of the combination of 3BNC117 and 10-1074 in HIV-uninfected adults","volume-title":"25th Conference on Retroviruses and Opportunistic Infections.","author":"Cohen","year":"2018"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","first-page":"20160001","DOI":"10.1515\/scid-2016-0001","article-title":"Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials","volume":"9","author":"Gilbert","year":"2017","journal-title":"Stat Commun Infect Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1080\/21645515.2018.1462640","article-title":"Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials","volume":"14","author":"Huang","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e25038","DOI":"10.1002\/jia2.25038","article-title":"Recent progress in immune-based interventions to prevent HIV-1 transmission to children","volume":"20","author":"Voronin","year":"2017","journal-title":"J Int AIDS Soc."},{"key":"B109","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/infdis\/175.2.283","article-title":"Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns","volume":"175","author":"Lambert","year":"1997","journal-title":"J Infect Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1086\/314637","article-title":"Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185","volume":"179","author":"Stiehm","year":"1999","journal-title":"J Infect Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/QAI.0b013e31822f8914","article-title":"Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB\/NVP STUDY)","volume":"58","author":"Onyango-Makumbi","year":"2011","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B112","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nm.4063","article-title":"Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques","volume":"22","author":"Hessell","year":"2016","journal-title":"Nat Med."},{"key":"B113","first-page":"329","article-title":"Safety and pharmacokinetics of a potent Anti-HIV monoclonal antibody, VRC01, in HIV-Exposed Newborns","author":"Cunningham","year":"2017","journal-title":"24th Conference on Retroviruses and Opportunistic Infections"},{"key":"B114","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/COH.0000000000000145","article-title":"Vectored antibody gene delivery for the prevention or treatment of HIV infection","volume":"10","author":"Deal","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"B115","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mt.2015.191","article-title":"Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in rhesus monkeys","volume":"24","author":"Martinez-Navio","year":"2016","journal-title":"Mol Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"16068","DOI":"10.1038\/mtm.2016.68","article-title":"Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies","volume":"3","author":"Fuchs","year":"2016","journal-title":"Mol Ther Methods Clin Dev."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T21:04:23Z","timestamp":1605301463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":116,"alternative-id":["10.3389\/fimmu.2018.02429"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02429","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"article-number":"2429"}}